articleThe LancetJun 1, 2022Closed access

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

University of Colorado Cancer Center · University of Colorado Denver · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

736
total citations
FWCI
71.14
Percentile
100%
References
15
Citations per year

Authors

21

Topics & keywords

Keywords
  • Medicine
  • Salvage therapy
  • Internal medicine
  • Rituximab
  • Transplantation
  • Oncology
  • Hematopoietic stem cell transplantation
  • Autologous stem-cell transplantation
No related works found for this paper.

Funding